There are several forms of the drug: NovoLog FlexPen* (prefilled, disposable insulin pen) NovoLog PenFill (insulin-filled cartridges that are used with a reusable insulin pen) NovoLog vial (used ...

Fiasp is an advanced version of NovoLog (insulin aspart), which also is injected ... which is a pre-filled, disposable pen, will fall from $559 to $140. For Tresiba’s U-100 FlexTouch, the ...

Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes ... a 3 mL single-use self-administered prefilled pen and a 10 mL multiple-dose vial.

Novo Nordisk, the manufacturer of NovoLog, also reported periodic shortages ... a dozen insulin products and more than 800 million insulin pens a year. "Not only are we not winding down our ...

NovoLog is also available in pen injector formats. Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart).

Merilog will be provided by prefilled pen in a 3 mL dose or in ... for those with commercial insurance. NovoLog and Novo Nordisk’s other rapid-acting insulin follow-on Fiasp are among the ...

months after cutting its price by 65% to $108 a vial and $162 for a 5-pack of injector pens. It has also reported shortages of NovoLog, another insulin product. The drugmakers run patient ...

Earlier this year, the drugmaker reported shortages of NovoLog insulin. Patients with Type 1 diabetes must take insulin to regulate their blood sugar because their bodies do not produce insulin.